Serologic Prevalence of Ebola Virus in Equatorial Africa.
Africa, Central
/ epidemiology
Antibodies, Viral
/ blood
Ebolavirus
/ immunology
Enzyme-Linked Immunosorbent Assay
HEK293 Cells
Hemorrhagic Fever, Ebola
/ blood
Humans
Immunoprecipitation
Nucleoproteins
/ immunology
Seroepidemiologic Studies
Viral Core Proteins
/ immunology
Viral Envelope Proteins
/ immunology
Cameroon
Democratic Republic of the Congo
ELISA
Ebola virus
Ghana
Republic of the Congo
Uganda
equatorial Africa
filovirus
hemorrhagic fever
hemorrhagic fever virus
luciferase immunoprecipitation system
neutralization assay
pseudotypes
serologic prevalence
viruses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
13
11
2019
Statut:
ppublish
Résumé
We conducted a serologic survey of 2,430 serum samples collected during 1997-2012 for various studies to determine the prevalence of the hemorrhagic fever virus Ebola virus (EBOV) in equatorial Africa. We screened serum samples for neutralizing antibodies by using a pseudotype microneutralization assay and a newly developed luciferase immunoprecipitation system assay. Specimens seroreactive for EBOV were confirmed by using an ELISA. Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region.
Identifiants
pubmed: 31002071
doi: 10.3201/eid2505.180115
pmc: PMC6478206
doi:
Substances chimiques
Antibodies, Viral
0
Nucleoproteins
0
Viral Core Proteins
0
Viral Envelope Proteins
0
envelope glycoprotein, Ebola virus
0
nucleoprotein VP40, Ebola virus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-918Subventions
Organisme : NIAID NIH HHS
ID : R21 AI107420
Pays : United States
Références
Clin Vaccine Immunol. 2016 Aug 05;23(8):717-24
pubmed: 27335383
Microbes Infect. 2005 Jun;7(7-8):1005-14
pubmed: 16002313
Elife. 2015 Nov 03;4:
pubmed: 26525597
Science. 2004 Jan 16;303(5656):387-90
pubmed: 14726594
PLoS Negl Trop Dis. 2015 Jun 05;9(6):e0003833
pubmed: 26047124
Am J Trop Med Hyg. 1983 Nov;32(6):1465-6
pubmed: 6650749
Trans R Soc Trop Med Hyg. 2015 Jun;109(6):366-78
pubmed: 25820266
J Virol. 2017 Aug 10;91(17):
pubmed: 28615211
Anesth Analg. 2015 Sep;121(3):798-809
pubmed: 26287303
PLoS One. 2014 Jun 10;9(6):e96360
pubmed: 24914933
Emerg Infect Dis. 2003 Dec;9(12):1531-7
pubmed: 14720391
PLoS One. 2010 Feb 09;5(2):e9126
pubmed: 20161740
Trans R Soc Trop Med Hyg. 2011 Aug;105(8):466-72
pubmed: 21605882
J Infect Dis. 2018 Jan 4;217(2):223-231
pubmed: 29253164
BMC Infect Dis. 2016 Jun 10;16:263
pubmed: 27286990
Transfusion. 2012 Feb;52(2):332-42
pubmed: 22239212
BMC Infect Dis. 2009 Sep 28;9:159
pubmed: 19785757
Nature. 2005 Dec 1;438(7068):575-6
pubmed: 16319873
BMC Biotechnol. 2005 Aug 18;5:22
pubmed: 16109166
J Gen Virol. 1992 Feb;73 ( Pt 2):347-57
pubmed: 1538192
J Infect Dis. 1999 Feb;179 Suppl 1:S102-7
pubmed: 9988172
Trans R Soc Trop Med Hyg. 1993 Sep-Oct;87(5):530-5
pubmed: 8266402
Am J Trop Med Hyg. 1988 Mar;38(2):407-10
pubmed: 3128130